Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands		Total	Annual Incentive Plan	Common Stock		Common Stock A&R Plan	Common Stock Annual Incentive Plan		Additional Paid-In Capital	[1]	Additional Paid-In Capital Annual Incentive Plan	[1]	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance, shares (in shares) at Mar. 31, 2023	[1]			23,059,998
Beginning balance at Mar. 31, 2023		$ 713,939		$ 2	[1]				$ 2,220,941				$ (620)	$ (1,506,384)
Issuance of common stock upon exercise of stock options (in shares)	[1]			9,036
Issuance of common stock upon exercise of stock options		85							85
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)	[1]					90,640	448,053
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan			$ 18,630								$ 18,630
Net share settlements for stock-based minimum tax withholdings (in shares)	[1]			(2,949)
Net share settlements for stock-based minimum tax withholdings		(121)							(121)
Stock-based compensation expense		47,915							47,915
Other comprehensive (loss) income		(334)											(334)
Net loss		(104,624)												(104,624)
Ending balance, shares (in shares) at Jun. 30, 2023	[1]			23,604,778
Ending balance at Jun. 30, 2023		675,490		$ 2	[1]				2,287,450				(954)	(1,611,008)
Beginning balance, shares (in shares) at Mar. 31, 2023	[1]			23,059,998
Beginning balance at Mar. 31, 2023		713,939		$ 2	[1]				2,220,941				(620)	(1,506,384)
Other comprehensive (loss) income		620
Net loss		(179,894)
Ending balance, shares (in shares) at Sep. 30, 2023	[1]			23,941,551
Ending balance at Sep. 30, 2023		625,251		$ 2	[1]				2,311,527				0	(1,686,278)
Beginning balance, shares (in shares) at Jun. 30, 2023	[1]			23,604,778
Beginning balance at Jun. 30, 2023		675,490		$ 2	[1]				2,287,450				(954)	(1,611,008)
Issuance of common stock upon exercise of stock options (in shares)	[1]			41,428
Issuance of common stock upon exercise of stock options		388							388
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)	[1]					217,919	2,900
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan			102								102
Net share settlements for stock-based minimum tax withholdings (in shares)	[1]			(951)
Net share settlements for stock-based minimum tax withholdings		(22)							(22)
Issuance of common stock under employee stock purchase plan (in shares)	[1]			75,477
Issuance of common stock under employee stock purchase plan		1,411							1,411
Stock-based compensation expense		22,198							22,198
Other comprehensive (loss) income		954											954
Net loss		(75,270)												(75,270)
Ending balance, shares (in shares) at Sep. 30, 2023	[1]			23,941,551
Ending balance at Sep. 30, 2023		625,251		$ 2	[1]				2,311,527				$ 0	(1,686,278)
Beginning balance, shares (in shares) at Mar. 31, 2024	[1]			24,505,970
Beginning balance at Mar. 31, 2024		188,520		$ 2	[1]				2,361,606					(2,173,088)
Issuance of common stock upon exercise of stock options (in shares)	[1]			6,889
Issuance of common stock upon exercise of stock options		58							58
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)	[1]					184,838	607,222
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan			$ 6,451				$ 1	[1]			$ 6,450
Net share settlements for stock-based minimum tax withholdings (in shares)	[1]			(4,415)
Net share settlements for stock-based minimum tax withholdings		(48)							(48)
Stock-based compensation expense		17,923							17,923
Net loss		(69,400)												(69,400)
Ending balance, shares (in shares) at Jun. 30, 2024	[1]			25,300,504
Ending balance at Jun. 30, 2024		143,504		$ 3	[1]				2,385,989					(2,242,488)
Beginning balance, shares (in shares) at Mar. 31, 2024	[1]			24,505,970
Beginning balance at Mar. 31, 2024		188,520		$ 2	[1]				2,361,606					(2,173,088)
Other comprehensive (loss) income		0
Net loss		(128,503)
Ending balance, shares (in shares) at Sep. 30, 2024	[1]			25,836,364
Ending balance at Sep. 30, 2024		101,929		$ 3	[1]				2,403,517					(2,301,591)
Beginning balance, shares (in shares) at Jun. 30, 2024	[1]			25,300,504
Beginning balance at Jun. 30, 2024		143,504		$ 3	[1]				2,385,989					(2,242,488)
Issuance of common stock upon release of restricted stock units under the 23andMe Second Amended and Restated Annual Incentive Plan (in shares)	[1]					484,051
Net share settlements for stock-based minimum tax withholdings (in shares)	[1]			(9,998)
Net share settlements for stock-based minimum tax withholdings		(70)							(70)
Issuance of common stock under employee stock purchase plan (in shares)	[1]			61,807
Issuance of common stock under employee stock purchase plan		331							331
Stock-based compensation expense		17,267							17,267
Other comprehensive (loss) income		0
Net loss		(59,103)												(59,103)
Ending balance, shares (in shares) at Sep. 30, 2024	[1]			25,836,364
Ending balance at Sep. 30, 2024		$ 101,929		$ 3	[1]				$ 2,403,517					$ (2,301,591)

[1] Amounts have been adjusted to reflect the reverse stock split that became effective on October 16, 2024. Refer to Note 2, “Summary of Significant Accounting Policies” and Note 19, “Subsequent Events,” for further information about the reverse stock split.